These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35289040)

  • 1. De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.
    Saffarian Z; Samii R; Ghanadan A; Vahidnezhad H
    Dermatol Ther; 2022 Jun; 35(6):e15448. PubMed ID: 35289040
    [No Abstract]   [Full Text] [Related]  

  • 2. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
    Akoglu G
    Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination.
    Norimatsu Y; Yoshizaki A; Yamada T; Akiyama Y; Toyama S; Sato S
    J Dermatol; 2023 Feb; 50(2):e74-e75. PubMed ID: 35906790
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.
    Falcinelli F; Lamberti A; Cota C; Rubegni P; Cinotti E
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e976-e978. PubMed ID: 35789506
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cases with new onset of pemphigus foliaceus after SARS-CoV-2 vaccination.
    Rouatbi J; Aounallah A; Lahouel M; Sriha B; Belajouza C; Denguezli M
    Dermatol Ther; 2022 Nov; 35(11):e15827. PubMed ID: 36111460
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemphigus foliaceus triggered after inactivated SARS-CoV-2 vaccine: Coincidence or causal link?
    Alami S; Benzekri L; Senouci K; Meziane M
    Dermatol Ther; 2022 Oct; 35(10):e15775. PubMed ID: 35976680
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al.
    Martora F; Fabbrocini G; Nappa P; Megna M
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e750-e751. PubMed ID: 35679165
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
    Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
    Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual presentation of pemphigus foliaceus following COVID-19 vaccination.
    Lua ACY; Ong FLL; Choo KJL; Yeo YW; Oh CC
    Australas J Dermatol; 2022 Feb; 63(1):128-130. PubMed ID: 34817063
    [No Abstract]   [Full Text] [Related]  

  • 12. A severe relapse of pemphigus vulgaris after SARS-CoV-2 vaccination.
    Ligrone L; Lembo S; Cillo F; Spennato S; Fabbrocini G; Raimondo A
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1369-e1371. PubMed ID: 37561928
    [No Abstract]   [Full Text] [Related]  

  • 13. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
    Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
    Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination.
    Jiao J; Shen Y; Wang P; Zuo K; Yang X; Chen M; Dong Y; Li J
    Front Biosci (Landmark Ed); 2022 Oct; 27(10):280. PubMed ID: 36336856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
    Hinterseher J; Hertl M; Didona D
    J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Wang H; Zhang Y; Huang B; Deng W; Quan Y; Wang W; Xu W; Zhao Y; Li N; Zhang J; Liang H; Bao L; Xu Y; Ding L; Zhou W; Gao H; Liu J; Niu P; Zhao L; Zhen W; Fu H; Yu S; Zhang Z; Xu G; Li C; Lou Z; Xu M; Qin C; Wu G; Gao GF; Tan W; Yang X
    Cell; 2020 Aug; 182(3):713-721.e9. PubMed ID: 32778225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
    Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
    Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Cousins with Acute Hemichorea after BBIBP-CorV (Sinopharm) COVID-19 Vaccine.
    Salari M; Etemadifar M
    Mov Disord; 2022 May; 37(5):1101-1103. PubMed ID: 35262222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.